Quanterix(US:QTRX)2025-05-12 21:24Financial Performance & Guidance - Quanterix's Q1 2025 revenue was $30.3 million, a 5% decrease compared to $32.1 million in Q1 2024 [38] - The company's adjusted cash burn was reduced by half, from $19.4 million in Q1 2024 to $9.0 million in Q1 2025 [13, 38] - Quanterix anticipates full year 2025 revenue to be between $120 million and $130 million [43] - The company projects GAAP gross margin between 55% and 59%, and adjusted gross margin between 50% and 54% for 2025 [44] - Quanterix expects adjusted cash burn of $35 to $45 million and total cash burn of $55 to $65 million for 2025 [45] Strategic Initiatives - Quanterix launched 4 new assays in Q1 2025 and expects to launch 15 new assays in 2025 [18] - The company is launching the Simoa ONE platform at the end of 2025, which is expected to be 10x more sensitive [22, 24] - Quanterix is developing tissue/blood complementary biomarker kits with Akoya, expected to launch in 2025 [29] - The equity value of the Akoya transaction decreased by 67%, from $201 million to $66 million [13] Non-GAAP Measures - Adjusted EBITDA margin was -37.4% in Q1 2025, compared to -25.4% in Q1 2024 [38, 49]